Antithrombin Glasgow II: alanine 382 to threonine mutation in the serpin P12 position, resulting in a substrate reaction with thrombin
- 1 September 1991
- journal article
- Published by Wiley in British Journal of Haematology
- Vol. 79 (1) , 70-74
- https://doi.org/10.1111/j.1365-2141.1991.tb08009.x
Abstract
A female with recurrent thrombosis was found to have a functional abnormality of antithrombin, with a ratio of functional to immunological activity in plasma of ∼ 50%. Crossed immunoelectrophoresis in the presence of heparin was normal, indicating an abnormality of the reactive site, rather than the heparin binding domain. Accordingly, the antithrombin was isolated by heparin‐Sepharose chromatography: this produced a mixture of normal and variant antithrombin, as the patient was heterozygous for the abnormality. To remove the normal component, the antithrombin was passed through a column of thrombin‐Sepharose. On sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS‐PAGE), prior to its application to thrombin‐Sepharose, the antithrombin migrated as a single band with identical mobility to that of normal antithrombin. After thrombin‐Sepharose, the purified variant component was proteolysed, and migrated as two components, one with a reduced and one with enhanced mobility under non‐reducing conditions. This demonstrated that the variant was unable to form stable inhibitor‐thrombin complexes and was cleaved in a substrate reaction with thrombin. One site of cleavage was unambiguously ascertained to be the Arg 393‐ Ser 394 reactive site bond, by NH2 terminal sequencing of the cleaved variant antithrombin: 10 steps beginning at the P 1’position, Ser‐Leu‐Asn‐Pro‐Asn‐Arg…., were clearly identified.The mutation responsible for this defect was studied by polymerase chain reaction (PCR) amplification of exon 6 of the antithrombin gene and direct sequencing of the amplified product. The presence of both a G and A in the first position of codon 382, identified the mutation GCA to ACA, which results in the substitution of Ala 382 to Thr. This is identical to that reported for antithrombin Hamilton (Devraj‐Kizuk et al, 1988), although antithrombin gene polymorphism analysis suggests that the antithrombin Glasgow II mutation has arisen independently.We have recently shown (Caso et al, 1991) that mutation at a nearby position, Ala 384 to Pro, also transforms another variant, antithrombin Vicenza/Charleville, into a substrate for thrombin. The present results with antithrombin Glasgow II suggest that all the alanine residues at the base of the reactive site loop in positions P12–10 may be important for the formation of a stabilized inhibitor‐thrombin complex.Keywords
This publication has 20 references indexed in Scilit:
- Antithrombin Vicenza, Ala 384 to Pro (GCA to CCA) mutation, transforming the inhibitor into a substrateBritish Journal of Haematology, 1991
- Crystal structure of ovalbumin as a model for the reactive centre of serpinsNature, 1990
- DdeI polymorphism in intron 5 of the ATIII geneNucleic Acids Research, 1990
- Implications of the three-dimensional structure of .alpha.1-antitrypsin for structure and function of serpinsBiochemistry, 1989
- Molecular characterization of antithrombin III (ATIII) variants using polymerase chain reaction. Identification of the ATIII Charleville as an Ala 384 Pro mutation.Journal of Clinical Investigation, 1989
- Antithrombin III Glasgow: a variant with increased heparin affinity and reduced ability to inactivate thrombin, associated with familial thrombosisBritish Journal of Haematology, 1987
- Antithrombin III Northwick Park: demonstration of an inactive high MW complex with increased affinity for heparinBritish Journal of Haematology, 1987
- Molecular Heterogeneity of Inherited Antithrombin III DeficiencyNew England Journal of Medicine, 1983
- Characterization of an unusual DNA length polymorphism 5' to the human antithrombin III geneNucleic Acids Research, 1983
- The active site of antithrombin. Release of the same proteolytically cleaved form of the inhibitor from complexes with factor IXa, factor Xa, and thrombin.Journal of Biological Chemistry, 1982